PR Newswire: news distribution, targeting and monitoring
Regulatory News Search

The Launch of a Breakthrough in the Control of Asthma: Introducing Lyprinol

LONDON, England, January 22 /PRNewswire/ -- - With picture

Asthma sufferers can now rely less on expensive preventative and relief medications, thanks to the recent discovery that the natural marine lipid extract, Lyprinol(TM) can provide significant relief of asthma symptoms following extensive international scientific and medical research.

Previously proven to be effective in helping people with painful, swollen or stiff joints, it has recently been discovered that Lyprinol(TM) - a patented, stabilised mix of marine lipids - helped people with asthma control their symptoms when taken as a nutritional supplement.

Research initiatives at the Queen Elizabeth Hospital and University of Adelaide in Australia, established that Lyprinol(TM) has a positive effect on the major inflammation pathways in the human body, reducing the damaging effects of persistent inflammation and possibly bringing relief to those who suffer from various allergic reactions, including asthma.

A study was completed in May 1999 of the efficacy and safety of Lyprinol(TM) with atopic asthma sufferers. The study was conducted by Dr. Alexander Emelyanov, Professor at the Hospital Therapeutic Clinic, Pavlov's St. Petersburg Medical University, in St. Petersburg, Russia and co-written with Professor Peter J. Barnes of the Royal Brompton Hospital in London - both eminent researchers in respiratory medicine. This study has recently been published in the European Respiratory Journal, Vol. 20, Issue 3 a top journal in the specialty. The patients taking Lyprinol(TM) noticed a reduced need for their inhalers by 50%.

Lyprinol is also used in the sports arena. Double gold medal winner in the Manchester Commonwealth games - Jana Pittman from Australia - suffered an asthma attack during the qualifications trials and only just qualified. She had been using her inhaler morning and night as well as taking preventive medicines. After two weeks on Lyprinol(TM) she noticed her breathing was easier and after 6 weeks she had stopped using preventative medication and only uses her inhaler before a race. Former Olympic swimmer Samantha Riley, a chronic sufferer since childhood, has also witnessed a dramatic reduction in her dependence on both reliever and preventative medicine.

There are countless species of mussels all over the world, but it is the New Zealand Green-Lipped Mussels, which contains a unique group of fatty acids which have been shown to affect inflammation pathways. Lyprinol(TM) is the result of 15 years research to identify the principal compounds interacting with inflammation pathways. It comprises a unique combination of different non-polar lipid groups and Omega-3 polyunsaturated fatty acids. These components are very sensitive to oxidation and exposure to heat or oxygen in processing often destroys their activity. Lyprinol(TM) uses a unique, patented process to extract these marine lipids, which protects their unique properties along with a delivery system. Decades of consumers using normal mussel powder products showed no improvement with Asthma until the lipids were extracted and delivered into the body correctly.

Introducing lyprinol

Helping to maintain healthy airways

Lyprinol is a marine lipid extract containing rare omega-3 fatty acids. It is a unique and natural anti-inflammatory with no known side effects or cross-reactions. Just one capsule per day can be taken by adults and children over the age of three years old with the benefits normally felt within 3 weeks. Lyprinol is available from Boots, Moss Pharmacy, Holland & Barrett and independent pharmacies - a pack of 30 capsultes retails at GBP12.95 (43p per day). Further information is available from

Asthma and breathing difficulties facts and figures

    - An estimated 8 million people in the UK have been diagnosed with asthma
      at some stage in their lives.
    - Incidence of asthma is now 3 to 4 times higher in adults and 6 times
      higher in children than it was 25 years ago.
    - In 2000, GPs in the UK saw over 18,000 cases relating to new
      asthma attacks each week.
    - An estimated 5.1 million people in the UK (1.4 million children
      and 3.7 million adults) are currently receiving treatment for asthma.
    - Currently 1,500 people still die from asthma each year, over a
      third are under the age of 65.
    - There are 74,000 emergency hospital admissions for asthma each
    - Treatment for asthma costs the NHS an estimated GBP850 million a
      year, but that is only a proportion of the total. Health costs per case
      of asthma increase according to how severe the person's asthma is and 
      how many attacks they have.
    - In a survey of 13-14 year olds carried out in 56 countries
      worldwide, the UK had the fifth highest prevalence rate for asthma.

High resolution photographs are available to the media free of charge at (+44 (0)207 608 1000)

SOURCE Lyprinol

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos and customised feeds just for media.

View and download archived video content distributed by MultiVu on The Digital Center.

Contact us now to find out how we can help you

Get content for your website

Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Start today.



Contact PR Newswire

Send us an email at or call us at +44 (0)20 7454 5382



Become a PR Newswire client

Request more information about PR Newswire products & services or call us at +44 (0)20 7454 5382


  1. Products & Services
  2. Knowledge Centre
  3. Browse News Releases
  4. Meet the Media
  5. Contact PR Newswire